

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- How George Tidmarsh crossed the FDA-industry Rubicon
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval















